Study to Evaluate the Safety of Repatha® in Pregnancy

NCT02906124 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 4

Last updated 2020-12-22

No results posted yet for this study

Summary

To evaluate pregnancy and infant outcomes among females diagnosed with familial hypercholesterolaemia (FH), exposed to Repatha® during pregnancy. This includes follow-up of their infants to the age of 12 months

Conditions

  • Hypercholesterolaemia
  • Pregnancy

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-12
Primary Completion
2020-11-06
Completion
2020-11-06

Countries

  • Australia
  • Austria
  • Belgium
  • Czechia
  • Denmark
  • Greece
  • Italy
  • Netherlands
  • Norway
  • Slovakia
  • Spain
  • Sweden
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02906124 on ClinicalTrials.gov